Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exscientia Plc - American Depositary Shares (NQ:EXAI)

4.840 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exscientia Plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Exscientia Business and Financial Update for the Full Year 2023
From Exscientia plc
Via Business Wire
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
Exscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
From Exscientia plc
Via Business Wire
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
From Exscientia
Via Business Wire
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
From Exscientia plc
Via Business Wire
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
From Exscientia plc
Via Business Wire
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Exscientia plc
Via Business Wire
Unlocking AI investment opportunities in healthcare
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exscientia Business Update for Third Quarter 2023
From Exscientia plc
Via Business Wire
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
From Exscientia plc
Via Business Wire
Parker Moss to Join Exscientia as EVP, Corporate Development
From Exscientia plc
Via Business Wire
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
From Exscientia plc
Via Business Wire
Exscientia Details Pipeline Prioritisation Strategy
From Exscientia plc
Via Business Wire
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in September
From Exscientia plc
Via Business Wire
Exscientia Business Update for Second Quarter and First Half of 2023
From Exscientia plc
Via Business Wire
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
From Exscientia
Via Business Wire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
MarketBeat Week in Review – 7/24 - 7/28
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week 
Via MarketBeat
Topics Economy
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges. 
Via MarketBeat
Topics Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
From Exscientia
Via Business Wire
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Exscientia Announces Expansion of its Technology Leadership Team
From Exscientia
Via Business Wire
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Exscientia plc
Via Business Wire
Exscientia Business Update for First Quarter 2023
From Exscientia plc
Via Business Wire
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
From Exscientia plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.